Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy-Reference-Cited by-同舟云学术

Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy

Published:2014-05 Issue:9 Volume:24 Page:2177-2181
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Perola Emanuele,Stamos Dean,Grillot Anne-Laure,Ronkin Steven,Wang Tiansheng,LeTiran Arnaud,Tang Qing,Deininger David D.,Liao Yusheng,Tian Shi-Kai,Drumm Joseph E.,Nicolau David P.,Tessier Pamela R.,Mani Nagraj,Grossman Trudy H.,Charifson Paul S.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference18 articles.

1. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

2. Effect of protein binding on antibiotic activity in vivo

3. Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics

4. The Clinical Relevance of Protein Binding and Tissue Concentrations in Antimicrobial Therapy

5. Effect of protein binding of daptomycin on MIC and antibacterial activity

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress in the discovery and development of DNA gyrase B inhibitors;Future Medicinal Chemistry;2018-05-01

2. Novel Antibacterial Compounds and their Drug Targets - Successes and Challenges;Current Medicinal Chemistry;2017-08-10

3. Modeling & Informatics at Vertex Pharmaceuticals Incorporated: our philosophy for sustained impact;Journal of Computer-Aided Molecular Design;2016-11-29

4. Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914);Journal of Medicinal Chemistry;2015-07-24

5. Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents;Journal of Medicinal Chemistry;2015-03-30